Home Granulocyte-Colony Stimulating Factor and Macrophage-Colony Stimulating Factor in Patients with Non-Small-Cell Lung Cancer
Article
Licensed
Unlicensed Requires Authentication

Granulocyte-Colony Stimulating Factor and Macrophage-Colony Stimulating Factor in Patients with Non-Small-Cell Lung Cancer

  • Barbara Mroczko , Maciej Szmitkowski and Jacek Niklinski
Published/Copyright: June 1, 2005
Become an author with De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 39 Issue 5

Abstract

We have investigated the serum level of granulocyte-colony stimulating factor (G-CSF) and macrophagecolony stimulating factor (M-CSF) in non-small-cell lung cancer (NSCLC), in relation to the control group and commonly accepted tumor markers, such as carcinoembryonic antigen (CEA) and cytokeratin fragment 19 (CYFRA 21-1). Additionally, we have defined the diagnostic sensitivity, specificity, positive predictive value, negative predictive value and receiver-operating characteristics (ROC) curve of G-CSF and M-CSF. Serum levels of cytokines were measured in 61 patients with NSCLC and in 20 healthy subjects. G-CSF and M-CSF were determined using ELISA. CYFRA 21-1 was measured by radioimmunoassay and CEA by microparticle enzyme immunoassay. There were significant increases in the level of circulating G-CSF in the lung cancer patients compared to the control group. Moreover, the diagnostic sensitivity of G-CSF was higher (56%) than the sensitivity of CYFRA 21-1 (51%), but lower than the CEA sensitivity (62%). The diagnostic specificity of G-CSF was higher (70%) than the M-CSF specificity (40%) and the G-CSF predictive values were higher in relation to the predictive values of M-CSF. These results suggest a potential role of G-CSF as a tumor marker for NSCLC.

:
Published Online: 2005-06-01
Published in Print: 2001-06-06

Copyright © 2001 by Walter de Gruyter GmbH & Co. KG

Articles in the same Issue

  1. SIBioC 2001 33rd National Congress of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology
  2. CCLM: The Near Future
  3. Granulocyte-Colony Stimulating Factor and Macrophage-Colony Stimulating Factor in Patients with Non-Small-Cell Lung Cancer
  4. Circulating Matrix Metalloproteinases and Their Inhibitors in Premature Coronary Atherosclerosis
  5. Real-Time Quantitative Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) for the Measurement of Prostate-Specific Antigen mRNA in the Peripheral Blood of Patients with Prostate Carcinoma Using the TaqManTM Detection System
  6. Serum Cardiac Troponin I after Conventional and Minimal Invasive Coronary Artery Bypass Surgery
  7. Improvement of the Quantitative Method for Glucose Determination Using Hexokinase and Glucose 6-Phosphate Dehydrogenase
  8. Conditions for Single-Strand Conformation Polymorphism (SSCP) Analysis of BRCA1 Gene Using an Automated Electrophoresis Unit
  9. Discrepancies between Apolipoprotein E Phenotyping and Genotyping in the Elderly
  10. Markers of Bone Turnover in Postmenopausal Women Receiving Hormone Replacement Therapy
  11. Reference Intervals for the Markers of Proteinuria with a Standardised Bed-Rest Collection of Urine
  12. The Friedewald Formula Underestimates LDL Cholesterol at low Concentrations
  13. The White Blood Cell Differential: Three Methods Compared
  14. Plasma Brain Natriuretic Peptide Measured by Fully-Automated Immunoassay and by Immunoradiometric Assay Compared
  15. Length of Sedimentation Reaction in Undiluted Blood (Erythrocyte Sedimentation Rate): Variations with Sex and Age and Reference Limits
  16. Biochemical Analysis of the Sperm and Infertility
  17. Evaluation of a Rapid Bedside Immunochromatographic Assay for Detection of Cardiac Troponin I in Whole Blood
  18. Correct Graphic Presentation of Method Comparison Data
  19. European Symposium on Clinical Laboratory and In Vitro Diagnostics Industry
Downloaded on 7.11.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2001.059/html
Scroll to top button